Article Details

Novartis's big wager on RNAi approaches the finish line

Retrieved on: 2020-11-25 15:30:45

Tags for this article:

Click the tags to see associated articles and topics

Novartis's big wager on RNAi approaches the finish line. View article details on hiswai:

Excerpt

... and, importantly, this looks to be in line with Amgen's Repatha and Sanofi/Regeneron's Praluent; both are <b>monoclonal antibodies</b> targeting PCSK9.

Article found on: www.evaluate.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up